[go: up one dir, main page]

MA26824A1 - 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase. - Google Patents

5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.

Info

Publication number
MA26824A1
MA26824A1 MA26585A MA26585A MA26824A1 MA 26824 A1 MA26824 A1 MA 26824A1 MA 26585 A MA26585 A MA 26585A MA 26585 A MA26585 A MA 26585A MA 26824 A1 MA26824 A1 MA 26824A1
Authority
MA
Morocco
Prior art keywords
heterocyclylsulfonylpyrid
dihydropyrazolo
pyrimidine
ones
substituted
Prior art date
Application number
MA26585A
Other languages
English (en)
Inventor
Moira Norfor Allerto Charlotte
Gordon Barber Christopher
Nigel Maw Graham
James Rawson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924041.8A external-priority patent/GB9924041D0/en
Priority claimed from GB0018660A external-priority patent/GB0018660D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA26824A1 publication Critical patent/MA26824A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26585A 1999-10-11 2002-04-04 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase. MA26824A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924041.8A GB9924041D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB0018660A GB0018660D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
MA26824A1 true MA26824A1 (fr) 2004-12-20

Family

ID=26244758

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26585A MA26824A1 (fr) 1999-10-11 2002-04-04 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.

Country Status (34)

Country Link
US (1) US6756373B1 (fr)
EP (1) EP1222190A1 (fr)
JP (1) JP2003511452A (fr)
KR (1) KR20020038941A (fr)
CN (1) CN1378547A (fr)
AP (1) AP2002002455A0 (fr)
AR (1) AR022665A1 (fr)
AU (1) AU7547900A (fr)
BG (1) BG106568A (fr)
BR (1) BR0014695A (fr)
CA (1) CA2387353A1 (fr)
CO (1) CO5261539A1 (fr)
CZ (1) CZ20021151A3 (fr)
DZ (1) DZ3218A1 (fr)
EA (1) EA200200240A1 (fr)
EE (1) EE200200192A (fr)
GT (1) GT200000168A (fr)
HK (1) HK1049834A1 (fr)
HU (1) HUP0203438A3 (fr)
IL (1) IL149025A0 (fr)
IS (1) IS6288A (fr)
MA (1) MA26824A1 (fr)
NO (1) NO20021695L (fr)
NZ (1) NZ517324A (fr)
OA (1) OA12058A (fr)
PA (1) PA8504401A1 (fr)
PE (1) PE20010736A1 (fr)
PL (1) PL357522A1 (fr)
SK (1) SK4562002A3 (fr)
SV (1) SV2002000192A (fr)
TN (1) TNSN00198A1 (fr)
TR (1) TR200200954T2 (fr)
UY (1) UY26383A1 (fr)
WO (1) WO2001027112A1 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (fr) * 2000-07-28 2002-01-30 Pfizer Inc. Procédé pour la préparation de pyrazoles
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
EP1575916B1 (fr) 2001-08-31 2013-05-22 The Rockefeller University Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
WO2003099194A2 (fr) * 2002-05-23 2003-12-04 Pfizer Limited Nouvelle combinaison
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
JP4208512B2 (ja) * 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
MXPA05011643A (es) 2003-04-29 2005-12-15 Pfizer Ltd 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
JP4838792B2 (ja) * 2004-03-05 2011-12-14 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Pde5阻害剤のための新規の使用
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ[4,3−d]ピリミジン類
ATE412648T1 (de) 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА
EP1888534B1 (fr) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Composés organiques
WO2007025103A2 (fr) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Composes organiques
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
EP1965863A2 (fr) * 2005-12-20 2008-09-10 Pfizer Products Inc. Combinaison pharmaceutique utilisee pour traiter des troubles urinaires du bas appareil (tuba)
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
EP2081431B1 (fr) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) * 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
ES2310144B1 (es) * 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EP2192903A4 (fr) * 2007-10-02 2010-09-29 Dong A Pharm Co Ltd Composition et méthode pour le traitement ou la prévention de l'hyperplasie bénigne de la prostate et des symptômes du tractus urinaire inférieur
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (fr) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Dérivés de Pyrazolopyrimidine-4,6-dione et leur utilisation pharmaceutique
MA32941B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
WO2010065147A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composés organiques
AU2009322900A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110944A1 (es) 2008-12-06 2012-01-25 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
BRPI0922348A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
CN102232077A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2379076B1 (fr) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
WO2010098839A1 (fr) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Inhibiteur de pde 1 pour troubles ophtalmiques
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2011153135A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2717877B1 (fr) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Composés organiques
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6437519B2 (ja) 2013-03-15 2018-12-12 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
EP3157926B1 (fr) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Composés organiques
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
RU2711442C2 (ru) 2014-09-17 2020-01-17 Интра-Селлулар Терапиз, Инк. Соединения и способы
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
CA2969594A1 (fr) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Composes organiques d'inhibition de pde2
WO2017172795A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
WO2019152697A1 (fr) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Nouvelles utilisations
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE69533057T2 (de) 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) 1995-01-20 2005-11-09 大正製薬株式会社 1H−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体
PL322452A1 (en) 1995-03-10 1998-02-02 Sanofi Pharmaceuticals 6-arylpyrasole [3,4-d]pyrimidin-4-ones, preparations containing such compounds and methods of mking use of them
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
HUP9601808A3 (en) 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
NZ338075A (en) 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ID27036A (id) * 1998-04-20 2001-02-22 Pfizer Pirazolopirimidinona penghambat cgmp pde5 untuk pengobatan kelainan fungsi seksual
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
BR9915532A (pt) 1998-10-23 2001-08-14 Pfizer Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20020173502A1 (en) * 2001-03-09 2002-11-21 Allerton Charlotte Moira Norfor Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
WO2003012095A1 (fr) 2001-07-28 2003-02-13 Midwest Research Institute Exoglucanase thermo-tolerante d'acidothermus cellulolyticus

Also Published As

Publication number Publication date
CN1378547A (zh) 2002-11-06
DZ3218A1 (fr) 2001-04-19
GT200000168A (es) 2002-04-03
AP2002002455A0 (en) 2002-06-30
NZ517324A (en) 2003-09-26
TNSN00198A1 (fr) 2002-05-30
NO20021695D0 (no) 2002-04-10
PA8504401A1 (es) 2002-04-25
HK1049834A1 (zh) 2003-05-30
OA12058A (en) 2006-05-03
SK4562002A3 (en) 2003-04-01
CZ20021151A3 (cs) 2003-03-12
WO2001027112A1 (fr) 2001-04-19
IL149025A0 (en) 2002-11-10
AU7547900A (en) 2001-04-23
EE200200192A (et) 2003-06-16
BG106568A (bg) 2002-12-29
NO20021695L (no) 2002-06-07
TR200200954T2 (tr) 2002-09-23
PE20010736A1 (es) 2001-07-19
CA2387353A1 (fr) 2001-04-19
US6756373B1 (en) 2004-06-29
KR20020038941A (ko) 2002-05-24
SV2002000192A (es) 2002-07-16
BR0014695A (pt) 2002-06-18
CO5261539A1 (es) 2003-03-31
HUP0203438A3 (en) 2003-05-28
UY26383A1 (es) 2001-05-31
AR022665A1 (es) 2002-09-04
EA200200240A1 (ru) 2002-10-31
EP1222190A1 (fr) 2002-07-17
JP2003511452A (ja) 2003-03-25
IS6288A (is) 2002-02-26
HUP0203438A2 (hu) 2003-01-28
PL357522A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
MA26824A1 (fr) 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
DE60037345D1 (de) Pyrroloi2,3-d pyrimidinderivate enthaltende Zusammensetzungen
NO20040540L (no) 4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
MA26881A1 (fr) 5-alkyl-pyrido [2,3-d]pyrimidines inhibitrices de tyrosine-kinases.
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
ID26698A (id) SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
MA26831A1 (fr) Derives de benzodiazepine."
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
DE60135854D1 (de) 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-one
NO20021694L (no) Pyrazolo[4,3-d]pyrimidinderivater
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
AU2002253794A1 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
DZ3266A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
DZ3036A1 (fr) Dérivés de monofluoroalkyles.
DK1294729T3 (da) 2-aminoalkyl-thieno[2,3-d]pyrimidiner
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
IT1321131B1 (it) Gruppo d'antenna per autoveicoli.
ITCS990004V0 (it) "termocamin0 c.c.m."
ZA200104710B (en) 4-Oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents.